Respiratory Management and Outcome of Preterm Infants
|
|
- Janel Parker
- 5 years ago
- Views:
Transcription
1 Respiratory Management and Outcome of Preterm Infants 6 th Annual Care Of The Sick Newborn Conference Shu Wu, MD. Department of Pediatrics Division of Neonatology University of Miami School of Medicine Prematurity and Pulmonary Morbidity 3,950,000 live birth in the USA in 2011 ~58,855 infants with birth weight <1,500g (VLBW) ~28,835 infants with birth weight <1,000g (ELBW) ELBW infants are at the highest risk for respiratory distress syndrome, bronchopulmonary dysplasia (BPD), and long-term pulmonary complications Bronchopulmonary Dysplasia (BPD) Bronchopulmonary Dysplasia (O 2 at 36 wks PMA), Years , NICHD BPD is the most common chronic lung disease of premature infants O 2 requirement >28 days at 36 weeks PMA Original BPD was first described in 1967 Moderately premature infants Pre-surfactant era, severe respiratory distress High pressure/volume MV and high levels of supplemental O 2 New BPD was introduced in 1999 ELBW infants <28 weeks GA Post-surfactant era, milder respiratory distress Increasing O 2 and MV needs over the first several weeks of life Prolonged O 2 need beyond 36 wk PMA UM NICU Admissions of Preterm Infants Birth Weight <1500g Survival to Discharge
2 O 2 dependent >36 wks CGA (% among survivors) 5/18/2015 O 2 Dependent 36 Weeks PMA BPD and Lung Developmental Stage < BW (grams) Embryonic Weeks Pseudoglandular Canalicular Saccular Alveolar Years Forming conducting airway -Birth of the acinus Preterm Birth at risk for BPD -Forming acinus -Epithelial differentiation -Airspace expansion -Secondary septation -Forming air-blood barrier -Producing surfactant -Capillary remodeling Lung Immaturity: Key in BPD 38 wk GA Intra-uterine 26 wk GA Normal alveoli Risk and Protective Factors for BPD Saccular??? Extra-uterine 38 wk PMA BPD Risk factors Protective factors Modified, Yodar et al, Neoreviews 2008, 9:e447 Strategies to Protect the Immature Lung Gentle ventilation: Patient triggered ventilation Adequate tidal volume/volume target Permissive hypercapnia Avoid invasive ventilation: CPAP, NIMV Avoid high inspired oxygen concentrations Pharmacological Approaches to Prevent and Treat BPD Acceleration of lung maturation: Antenatal steroids Treating RDS: Surfactant replacement Prevent and treat infection: Azithromycin Anti-inflammation: Postnatal steroids Treating apnea: Caffeine Decrease pulmonary edema: Diuretics Bronchodilators: Albuterol, Atrovent Pulmonary vasodilators: ino, sildenafil Nutritional supplements: Vitamin A 2
3 Antenatal Steroids First discovered in 1969 in animal studies to enhance lung maturation First RCT was conducted in 1972 to prevent RDS in preterm deliveries Large RCTs in preterm delivery have shown: Reduction of mortality and RDS Reduction of IVH and NEC Does not increase the risk of sepsis Long-term Effects of Antenatal Steroids Outcome Number of birth (n) 23 weeks GA ANS No ANS OR 95% CI Survival to discharge * (%) Survival w/o O 2 at 36 wks (%) Survival to F/U (%) Survival w/o NDI (%) * * * NICHD Neonatal Research Network, Carlo W et al, Ped Res, weeks GA ANS No ANS OR 95% CI * * * * P<0.001 Surfactant Replacement Was established as an effective and safe therapy for immaturity-related surfactant deficiency by early 1990s Surfactant Preparations and Recommended Doses Generic name Trade Name Source Dose Bovactant Alveofact Bovine 50 mg/kg/dose Improves survival of preterm infants Bovine lipid extract surfactant BLES Bovine 135 mg/kg/dose Reduces incidence and severity of RDS Reduces incidence of pneumothorax Additive effect with antenatal steroids Poractant alfa Curosurf Porcine 200 mg/kg/dose Calfactant Infasurf Bovine 105 mg/kg/dose Surfactant-TA Surfacten Bovine 100 mg/kg/dose Beractant Survanta Bovine 100 mg/kg/dose Colfoseril palmitate Exosurf Synthetic 64 mg/kg/dose Use of Azithromycin for the Prevention of BPD Outcome Azithromycin (n=111) Placebo (n=109) Birth weight (g) 803± ±188 Gestational age 25.7±1.5 26±1.6 Incidence of Ureaplasma 31% 40% P value Days of MV 28±26 26± Days of O 2 65±40 64± Ureaplasma positive BPD or death 73% (19/26) 94% (33/35) 0.03 Postnatal Corticosteroids in Preterm Infants Have been used since the 1970s to ameliorate lung inflammation in ventilated preterm infants In the middle of 1990s, 25-50% of all very low birth weight infants received postnatal steroids: Facilitates extubation and improves lung compliance No effect on duration of supplemental O 2, duration of hospitalization or mortality In 2001, meta-analyses highlighted the association between postnatal steroids and impaired neurodevelopment Ballard HO, et al, Pediatric Pulmonology, 46:111,
4 Meta-analyses Assessing the Timing of Postnatal Steroids Administration Age Effect Outcome Evidence < 7 days Short-term Long-term Short-term Ventilation Mortality CLD Cerebral palsy Ventilation Extubation rate No change Reduced risk Increased risk Extubation rate OR 0.75 ( ) OR 1 ( ) OR 0.76 ( ) OR 1.45 ( ) OR 0.62 ( ) Caffeine Is one of the most commonly used medication in NICU for apnea of prematurity Can enhance central respiratory drive 7-14 days Long-term Mortality CLD Cerebral palsy No change Reduced risk No difference OR 0.66 ( ) OR 0.62 ( ) OR 0.83 ( ) Can improve minute ventilation, pulmonary mechanics and respiratory muscle contractility >21 days Short-term Long-term Ventilation Mortality CLD Cerebral palsy Yates HL, Arch Di Child Fetal neonatal ED, 97:F299, 2012 Extubation rate No change Reduced risk No difference OR 0.69 ( ) OR 1.03 ( ) OR 0.76 (0.58-1) OR 1.2 ( ) Prevent lung inflammation? Caffeine Therapy for Apnea of Prematurity (CAP Trial) Short Term Outcome CAP Trial-Long Term Outcome Outcome Caffeine (n=1006) Placebo (n=1000) Birth weight (g) 964± ±181 OR (95% CI) Death 5.2% 5.5% 0.93 ( ) NEC 6.3% 6.7% 0.93 ( ) Brain injury by US 13% 14.3% 0.97 ( ) Weight gain -23g (-32 to -13) BPD at 36 weeks PMA 36.3% 46.9% 0.64 ( ) PDA/drug therapy 29.3% 38.1% 0.67 ( ) PDA/surgical closure 4.5% 12.6% 0.29 ( ) At 18 months corrected age Caffeine (n=833) Placebo (n=807) P value Death 6.8% 6.9% 0.99 Cerebral palsy 4.3% 7.7% MDI < % 36.6% 0.03 MDI < % 16.2% 0.02 At 5 years corrected age Death/at least 1 impairment 21.1% 24.8% 0.09 Full scale IQ< % 19.4% 0.44 Schmidt B. NEJM, 354: , 2006 Schmidt B, JAMA 307:3, 2012 Diuretic Therapy in Preterm Infants Commonly used loop diuretics: Furosemide, Thiazide ± Spironolactone Rationale: Lung edema, PDA, renal insufficiency Potential benefits: Improvement in lung function Risks: Electrolyte imbalance, ototoxicity, renal Ca + No evidence of benefit on clinical outcomes: Mortality, duration of ventilation and O 2, BPD No evidence to support routine use Bronchodilators Albuterol (Inhaled b 2 -agonist): Used in BPD with reversible bronchospasm Short-term improvements in pulmonary resistance and compliance Long-term efficacy has not been established May develop tolerance with prolonged use Atrovent (Ipratropium bromide): A muscarinic antagonist Clinical trials did not show efficacy in BPD progression or long-term respiratory status Consider to be used if wheezing and not responding to albuterol 4
5 Inhaled Nitric Oxide (ino) Is a selective pulmonary vasodilator Is an effective therapy for pulmonary hypertension and hypoxic respiratory failure in term infants Prevent or treat BPD in preterm infant? INO in Preterm Infants Meta-analysis (Askie LM, Pediatrics 2011;128:729) In preterm infants <34 wk gestation: 14 trials were conducted 11 trials were analyzed from 1997 to 2010 Total 3298 infants NIH consensus: evidence does not support use of ino in the care of preterm infants <34 wk GA Primary Outcome Secondary Outcome Askie LM, Pediatrics 2011;128:729 Askie LM, Pediatrics 2011;128:729 Sildenafil Is a selective type 5 phosphodiesterase inhibitor that increases cgmp and causes vasodilation Can be given orally, and over long periods of time with apparent low toxicity Reported increased mortality in older children with high doses Using off-label for the treatment of pulmonary hypertension caused by BPD Vitamin A Vitamin A is necessary for normal lung growth and the integrity of respiratory tract epithelial cells Preterm infants have low vitamin A status at birth, and this has been associated with increased risk of developing chronic lung disease Recommend does: 5000 IU/dose, im, 3/week 5
6 Vitamin A Supplementation for Extremely Low Birth Weight Infants Long-term Lung Function in BPD and Full-term Infants Outcome Vitamin A Placebo P value (n=405) (n=402) Birth wt (g) 770± ±138 Death 17% 16% 0.96 CLD at 36 wks 47% 56% 0.03 Tyson JE, NICHD Neonatal Research Newtwork, NEJM, 340:25, 1999 Seminars in Fetal & Neonatal Med 2013;1-7 Chronic Respiratory Morbidity Needing supplementary oxygen at home Recurrent respiratory symptoms: Coughing, wheezing, asthma, pneumonia Re-hospitalization Abnormal lung function: Lower lung volumes, airway obstruction Lower forced expiratory flows, reduced diffusing capacities Pulmonary abnormalities on imaging: Persistent up to young adulthood Pulmonary hypertension: Abnormal echocardiogram Confirmation by cardiac catheterization Increasing mortality One-Year Respiratory Outcomes of Preterm Infants in the Nitric Oxide to Prevent Chronic Lung Disease Trial Total 455 infants Birth weight (g) 765 ± 156 Gestational age (wks) 25.8 ± 1.4 Any home O 2 (%) 44 Persistent home O 2 (%) 6.2 Bronchodilator use (%) 47.1 Inhaled steroid use (%) 26.1 Systemic steroid use (%) 14.4 Diuretic use (%) 23.5 Any hospitalization (%) 48.5 Respiratory hospitalization (%) 22.3 J Pediatr 2008;153:525-9 Respiratory Symptoms and Lung Function at 11 Years in Children Born Extremely Preterm (The EPICure Study) Lung Function after Preterm Birth: Development from Mid-Childhood to Adulthood All EP Classmates (C) EP C Δ (95% CI) n Gestational age at birth, wks 25.0 (0.7) 36 Age, years 10.9 (0.38) 10.9 (0.55) 0.0 ( 0.1; 0.1) Current asthma 42 (25%) 20 (13%) 12% (4; 21%), P<0.01 Asthma medication 41 (25%) 16 (11%) 14% (6; 22%), P<0.01 Seen by respiratory specialist 14 (8%) 4 (3%) 6% (1; 11%), P<0.05 Exercise-induced wheeze 34 (21%) 13 (9%) 12% (4; 19%), P<0.01 Nocturnal cough 33 (20%) 16 (11%) 9% (1; 17%), P<0.05 zfev1-1.4 (1.2) 0.0 (1.0) -1.5 (-.17; -1.2), P<0.001 Am J Respir Crit Care Med, 2010;182: Thorax, 2013;68:
7 CXR and Chest CT of BPD Contrast Tracheobronchogram of BPD CXR from a 4 month old boy (ex-24 week) with severe BPD Chest CT from a 2 year old boy (ex-24 week) with severe BPD Contrast tracheobronchogram from an ex 24 week preterm infant with a persistent CPAP requirement. Inspiratory (A) and expiratory (B) images demonstrating marked reduction in calibre of both left and right sided large airways on expiration. Andrew C. Wilson, Pediatric Respiratory Reviews, Volume 11, Issue 3, 2010, Andrew C. Wilson, Pediatric Respiratory Reviews, Volume 11, Issue 3, 2010, Chest CT Findings in BPD Chest CT Findings in BPD and Correlation with Lung Function Hyperlucence and linear opacities Triangular subpleural opacities Arch Dis Child Fetal Neonatal Ed 2007;92:F Total 41 patients Birth weight (g), mean (SD) 914 (37) Gestation age (weeks), mean (SD) 27.2 (0.2) Duration of O 2 supplement (days), mean (SD) 68 (6) PMA at end O 2 supplement (weeks), mean (SD) 37 (0.7) CT, months of age Hyperlucent areas, n (%) 36 (88%) Linear opacities, n (%) 39 (95%) Triangular subpleural opacities, n (%) 26 (63%) Mahut etal, Arch Dis Child Fetal Neonatal Ed 2007;92:F Chest CT Findings in BPD and Correlation with Lung Function Chest CT Findings in BPD and Correlation with Lung Function P < 0.05 P < 0.05 P < 0.02 r = , P < 0.02 r = , P < 0.02 Arch Dis Child Fetal Neonatal Ed 2007;92:F Arch Dis Child Fetal Neonatal Ed 2007;92:F
8 Pulmonary Hypertension in BPD: Clinical Findings, Cardiovascular Anomalies and Outcomes Total 29 patients Median diagnosis of PH (months) 4.5 ( ) Echo RVP/SP (%) 70 (60-80) Cardiac catheterization (n) 14 Aortopulmonary collaterals (n) Pulmonary vein stenosis (n) ASD (n) PDA (n) Median fellow up (months) 35 (21-91) Spontaneous resolved PH (n) PH medications (n) Shunt closure (n) Death (n) Cerro etal Pediatric Pulmonology, 2013;49:49-59 Pulmonary Hypertension in BPD A and B: Pulmonary wedge angiographies of patients showing variable degrees of vascular hypoplasia. septum (IVS) morphology on echocardiography C and D: Lung perfusion before scintigraphy and CT scans and after the specific PH showing drug stenosis treatment. of the left b: pulmonary veins and Pulmonary hypertension (PH) hypoperfusion outcome of the left lung. after treatment. E: Aortogram at 12 months old. F: Aortogram at 4 years old. Showing filling of the lower lobe pulmonary arteries from aortic collaterals.. Pediatric Pulmonology, 2013;49:49-59 BPD with Pulmonary Hypertension: Mortality Take Home Message! Preterm birth is a significant global heath problem The incidence of BPD is not decreasing There is no effective therapy for BPD Long-term pulmonary morbidities of BPD survivors are concerning It is imperative that lung function of these patients be closely monitored Pediatric Pulmonology, 2013;49:49-59 Thank You! 8
An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy
An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy Housekeeping: I have no financial disclosures Learning objectives: Develop an understanding of bronchopulmonary dysplasia (BPD)
More informationChronic Lung Disease Of Prematurity. Dr Jo Harrison
Chronic Lung Disease Of Prematurity Dr Jo Harrison 9.9.14 Chronic Neonatal Lung Disease Bronchopulmonary dysplasia (BPD) first described in 1967 by Northway Defined as O 2 dependence at 28 days post birth
More informationNoah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018
Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for
More informationBRONCHOPULMONARY DYSPLASIA
BRONCHOPULMONARY DYSPLASIA CHRONIC NEONATAL LUNG DISEASE (CLD) 2 2 nd BERLIN NEONATOLOGY SUMMER SCHOOL September 2014 3 Mt. Scopus 4 Ein Kerem 5 BRONCHOPULMONARY DYSPLASIA 1960: Ventilation of Neonates
More informationLate pulmonary hypertension in preterm infants How to sort things out? V.Gournay, FCPC, La Martinique, Nov 23,2015
Late pulmonary hypertension in preterm infants How to sort things out? V.Gournay, FCPC, La Martinique, Nov 23,2015 Epidemiology Incidence of extreme prematurity (
More informationMinimizing Lung Damage During Respiratory Support
Minimizing Lung Damage During Respiratory Support University of Miami Jackson Memorial Medical Center Care of the Sick Newborn 15 Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson
More informationObjectives. Apnea Definition and Pitfalls. Pathophysiology of Apnea. Apnea of Prematurity and hypoxemia episodes 5/18/2015
Apnea of Prematurity and hypoxemia episodes Deepak Jain MD Care of Sick Newborn Conference May 2015 Objectives Differentiating between apnea and hypoxemia episodes. Pathophysiology Diagnosis of apnea and
More informationUSE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014
USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014 ino for Late Preterm and Term Infants with Severe PPHN Background:
More informationIs There a Treatment for BPD?
Is There a Treatment for BPD? Amir Kugelman, Pediatric Pulmonary Unit and Department of Neonatology Bnai Zion Medical Center, Rappaport Faculty of Medicine Haifa, Israel Conflict of Interest Our study
More informationPATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT
PATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT Dr. Youssef Abou Zanouna, FRCPI, FACC Consultant Pediatric Cardiologist King Fahd Military Medical Complex Dhahran Introduction
More informationBest Practices in Bronchopulmonary
Best Practices in Bronchopulmonary Dysplasia a (BPD) Prevention e Matthew M. Laughon, MD, MPH Professor of Pediatrics The University of North Carolina at Chapel Hill I receive support from the U.S. government
More informationQuality Improvement Approaches to BPD. Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana
Quality Improvement Approaches to BPD Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana goldsmith.jay@gmail.com No conflicts of interest to declare There is nothing more dangerous to the
More informationHyaline membrane disease. By : Dr. Ch Sarishma Peadiatric Pg
Hyaline membrane disease By : Dr. Ch Sarishma Peadiatric Pg Also called Respiratory distress syndrome. It occurs primarily in premature infants; its incidence is inversely related to gestational age and
More informationPatent Ductus Arteriosus: Philosophy or Pathology?
Patent Ductus Arteriosus: Philosophy or Pathology? Disclosure Ray Sato, MD is a speaker for Prolacta Biosciences, Inc. This presentation will discuss off-label uses of acetaminophen and ibuprofen. RAY
More informationOverview of Bronchopulmonary Dysplasia
Overview of Bronchopulmonary Dysplasia Terrence W. Carver, Jr., M.D. Children s Mercy Hospitals and Clinics Medical Director of Respiratory Care and Pulmonary Medicine Associate Professor of Pediatrics
More informationUpdate on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha
Update on mangement of patent ductus arteriosus in preterm infants Dr. Trinh Thi Thu Ha Outline 1. Overview of PDA 2. Timing of screening PDA? 3. When to treat PDA? Timing of ductal closure Prenatal
More informationKugelman A, Riskin A, Said W, Shoris I, Mor F, Bader D.
Heated, Humidified High-Flow Nasal Cannula (HHHFNC) vs. Nasal Intermittent Positive Pressure Ventilation (NIPPV) for the Primary Treatment of RDS, A Randomized, Controlled, Prospective, Pilot Study Kugelman
More informationDisclosures. Learning Objectives. Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach 3/10/2017
Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach Steven H. Abman, MD Professor, Department of Pediatrics Director, Pediatric Heart Lung Center University of Colorado School
More informationDISCLOSURE FUNDING BRONCHOPULMONARY DYPLASIA (BPD) UCSF. Preventing BPD: Is Inhaled Nitric Oxide the Answer? March, 2009
Preventing BPD: Is Inhaled Nitric Oxide the Answer? March, 2009 Roberta A. Ballard Professor of Pediatrics UCSF DISCLOSURE INO THERAPEUTICS (IKARIA) has provided: * Inhaled Nitric Oxide (INOmax) * Delivery
More informationDr. AM MAALIM KPA 2018
Dr. AM MAALIM KPA 2018 Journey Towards Lung protection Goals of lung protection Strategies Summary Conclusion Before 1960: Oxygen; impact assessed clinically. The 1960s:President JFK, Ventilators mortality;
More information** SURFACTANT THERAPY**
** SURFACTANT THERAPY** Full Title of Guideline: Surfactant Therapy Author (include email and role): Stephen Wardle (V4) Reviewed by Dushyant Batra Consultant Neonatologist Division & Speciality: Division:
More informationRango de saturacion de oxigeno: Cual es la evidencia?
Rango de saturacion de oxigeno: Cual es la evidencia? Wally Carlo, M.D. University of Alabama at Birmingham Department of Pediatrics Division of Neonatology wcarlo@peds.uab.edu 1 2 Stevie Wonder 4 Objectives
More informationHazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida
Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Disclosures I have no financial affiliations or relationships to disclose. I will
More informationAEROSURF Phase 2 Program Update Investor Conference Call
AEROSURF Phase 2 Program Update Investor Conference Call November 12, 2015 Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements
More informationOriginal Policy Date
MP 8.01.17 Inhaled Nitric Oxide Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy Index
More informationFrom Chronic Lung Disease of Infancy to Asthma
From Chronic Lung Disease of Infancy to Asthma Mollie V. Anderson, CPNP Certified Pediatric Nurse Practitioner Pediatric Lung Care Bon Secours Medical Group St. Mary s Hospital 1 Mollie V. Anderson, CPNP
More informationPEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE GUIDELINES Pharmacologic Strategies for the Prevention of Bronchopulmonary Dysplasia
PEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE GUIDELINES Pharmacologic Strategies for the Prevention of Bronchopulmonary Dysplasia Clinical Practice Guideline: Pharmacologic Strategies for the Prevention
More informationSTOP ROP The STOP-ROP Multicenter Study Group: Pediatrics 105:295, 2000 Progression to Threshold Conventional Sat 89-94% STOP ROP
Hrs TcPO2 > 80 nnhg (weeks 1 4) OXYGEN TARGETS: HOW GOOD ARE WE IN ACHIEVING THEM Oxygen Dependency GA wks Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson Memorial Medical Center
More informationEvaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants
Evaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants by Amber Elise Reichert A thesis submitted in partial fulfilment of
More informationName and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi
Protocol title: Heated, Humidified High-Flow Nasal Cannula vs Nasal CPAP for Respiratory Distress Syndrome of Prematurity. Protocol identifying number: Clinical Trials.gov NCT02570217 Name and title of
More informationReview of Neonatal Respiratory Problems
Review of Neonatal Respiratory Problems Respiratory Distress Occurs in about 7% of infants Clinical presentation includes: Apnea Cyanosis Grunting Inspiratory stridor Nasal flaring Poor feeding Tachypnea
More informationBubble CPAP for Respiratory Distress Syndrome in Preterm Infants
R E S E A R C H P A P E R Bubble CPAP for Respiratory Distress Syndrome in Preterm Infants JAGDISH KOTI*, SRINIVAS MURKI, PRAMOD GADDAM, ANUPAMA REDDY AND M DASARADHA RAMI REDDY From Fernandez Hospital
More informationAdvances in Pulmonary Hypertension Workshop BPD: Challenges in Lung and Pulmonary Vascular Growth and Development
Advances in Pulmonary Hypertension Workshop BPD: Challenges in Lung and Pulmonary Vascular Growth and Development Moderators: Drs. Roberta L. Keller + Nicolas Porta March 9, 2017 Workshop Faculty Roberta
More informationOxygenation. Chapter 45. Re'eda Almashagba 1
Oxygenation Chapter 45 Re'eda Almashagba 1 Respiratory Physiology Structure and function Breathing: inspiration, expiration Lung volumes and capacities Pulmonary circulation Respiratory gas exchange: oxygen,
More informationBPD. Neonatal/Pediatric Cardiopulmonary Care. Disease. Bronchopulmonary Dysplasia. Baby Jane
1 Neonatal/Pediatric Cardiopulmonary Care Disease 2 Bronchopulmonary Dysplasia 3 is a 33-day-old prematurely born girl who weighs 1420 g. At birth, her estimated gestational age was 28 weeks. Her initial
More informationSurfactant Administration
Approved by: Surfactant Administration Gail Cameron Senior Director Operations, Maternal, Neonatal & Child Health Programs Dr. Paul Byrne Medical Director, Neonatology Neonatal Policy & Procedures Manual
More informationSimulation 08: Cyanotic Preterm Infant in Respiratory Distress
Flow Chart Simulation 08: Cyanotic Preterm Infant in Respiratory Distress Opening Scenario Section 1 Type: DM As staff therapist assigned to a Level 2 NICU in a 250 bed rural medical center you are called
More informationNeonatal/Pediatric Cardiopulmonary Care. Persistent Pulmonary Hypertension of the Neonate (PPHN) PPHN. Other. Other Diseases
Neonatal/Pediatric Cardiopulmonary Care Other Diseases Persistent Pulmonary Hypertension of the Neonate (PPHN) PPHN 3 Also known as Persistent Fetal Circulation (PFC) Seen most frequently in term, post-term
More informationINTRODUCTION The effect of CPAP works on lung mechanics to improve oxygenation (PaO 2
2 Effects of CPAP INTRODUCTION The effect of CPAP works on lung mechanics to improve oxygenation (PaO 2 ). The effect on CO 2 is only secondary to the primary process of improvement in lung volume and
More informationNewborn Life Support. NLS guidance.
Kelly Harvey, ANNP NWNODN, previously Wythenshawe Hospital has shared this presentation with the understanding that it is for personal use following your attendance at the 8th Annual Senior Neonatal Nursing
More informationSURFACTANT UPDATE. George Mandy, M.D. Nationwide Children s Hospital The Ohio State University
SURFACTANT UPDATE George Mandy, M.D. Nationwide Children s Hospital The Ohio State University Surfactant Update Objectives History Meta-analysis of surfactant therapy New synthetic surfactant Genetic disorders
More informationPlanning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll, MD
Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll,
More informationROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME
INDIAN PEDIATRICS VOLUME 35-FEBRUAKY 1998 ROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME Kanya Mukhopadhyay, Praveen Kumar and Anil Narang From the Division of Neonatology, Department
More informationThe Basics. Editorial Team. Editorial Team 9/28/2017
Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll,
More informationShort-Term Outcome Of Different Treatment Modalities Of Patent Ductus Arteriosus In Preterm Infants. Five Years Experiences In Qatar
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 2 Short-Term Outcome Of Different Treatment Modalities Of Patent Ductus Arteriosus In Preterm Infants. Five Years Experiences In
More informationInsults to the Developing Brain & Effect on Neurodevelopmental Outcomes
Insults to the Developing Brain & Effect on Neurodevelopmental Outcomes Ira Adams-Chapman, MD Assistant Professor of Pediatrics Director, Developmental Progress Clinic Emory University School of Medicine
More information1
1 2 3 RIFAI 5 6 Dublin cohort, retrospective review. Milrinone was commenced at an initial dose of 0.50 μg/kg/minute up to 0.75 μg/kg/minute and was continued depending on clinical response. No loading
More informationRescue Therapies in Neonatology. February 2014 Bill Walsh Monroe Carell Jr Children s Vanderbilt
Rescue Therapies in Neonatology February 2014 Bill Walsh Monroe Carell Jr Children s Vanderbilt Off Label Use-Disclaimer All discussion in this talk concerns off-label use of nitric oxide, steroids, and
More informationDiuretic Use in Neonates
Neonatal Nursing Education Brief: Diuretic Use in the Neonate http://www.seattlechildrens.org/healthcareprofessionals/education/continuing-medical-nursing-education/neonatalnursing-education-briefs/ Diuretics
More informationWhat s new in neonatal resuscitation?
What s new in neonatal resuscitation? Anup Katheria, M.D. Director, Neonatal Research Institute Sharp Mary Birch Hospital for Women & Newborns Disclosures I have no financial Disclosures. Overview Delivery
More informationThree Decades of Managing Congenital Diaphragmatic Hernia
Three Decades of Managing Congenital Diaphragmatic Hernia Desmond Bohn The Department of Critical Care Medicine The Hospital for Sick Children, Toronto Robert E Gross Congenital Diaphragmatic Hernia 1960-80
More informationPulmonary Surfactant. Jian kang, M.D. Pediatric PGY-2
Pulmonary Surfactant Jian kang, M.D. Pediatric PGY-2 Objectives Functions Composition Metabolism Applications Functions To increase pulmonary compliance To prevent the lung from collapsing at the end of
More informationDepartment of Pediatrics, Shin Kong WHS Memorial Hospital, Taipei, Taiwan. 3
ORIGINAL ARTICLE The Use of Montelukast in Six Ventilator Dependent Infants Cheng I 1,2, Tsai Li-Yi 2, Chen Yi-Lin 2, Ho Shih-Ping 2, Mu Shu-Chi 2,3,4 1 Department of Pediatrics, Taitung Christian Hospital,
More informationWaiting to Inhale Jeopardy
Waiting to Inhale: RDS, BPD, and Assisted Ventilation of the Neonate Steven R. Seidner, M.D. Professor of Pediatrics Chief, Division of Neonatal-Perinatal Medicine Waiting to Inhale Jeopardy RDS Surfactant
More informationProvide guidelines for the management of mechanical ventilation in infants <34 weeks gestation.
Page 1 of 5 PURPOSE: Provide guidelines for the management of mechanical ventilation in infants
More informationPULMONARY VENOLOBAR SYNDROME. Dr.C.Anandhi DNB Resident, Southern Railway Headquarters Hospital.
PULMONARY VENOLOBAR SYNDROME Dr.C.Anandhi DNB Resident, Southern Railway Headquarters Hospital. Presenting complaint: 10 yrs old girl with recurrent episodes of lower respiratory tract infection from infancy.
More informationAim: Reduction in the rate of CLD in ELBW infants (<1000 grams) by 30% from its baseline of 72 % by January 2016.
LIVE (Less Invasive Ventilation of ELBW infants) HEALTHY WVU Children s Hospital, Morgantown, WV, USA Rebecca Tilley, RN; Jamie Karr, RT; Tiffany Blosser, RN; Christy Dixon, RT; Melinda Connolly, ANP;
More informationFANNP 28TH NATIONAL NNP SYMPOSIUM: CLINICAL UPDATE AND REVIEW OCTOBER 17-21, 2017
Pulse Oximetry in the Delivery Room: Principles and Practice GS2 3 Jonathan P. Mintzer, MD, FAAP Assistant Professor of Pediatrics Stony Brook Children s Hospital, Division of Neonatal-Perinatal Medicine,
More informationNeonatal and Pediatric Pulmonary Vascular Disease
Neonatal and Pediatric Pulmonary Vascular Disease Emma Olson, MS, ARNP Pediatric Cardiology Nurse Practitioner Canadian Respiratory Conference April 14, 2018 Financial Interest Disclosure (over the past
More informationCOMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY
CASE STUDIES COMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY Gabriela Ildiko Zonda 1, Andreea Avasiloaiei 1, Mihaela Moscalu 2, Maria Stamatin 1
More informationLectures 4 Early fetal assessment, screening, ultrasound and treatment modalities during pregnancy. II. Asphyxia and Resuscitation (3 lectures)...
Outline of a 2 year Neonatology educational course (80 lectures) PLUS 2 graduate level courses (GENETICS and BIOSTATISTICS & EPIDEMIOLOGY Approximate Percent in Examination I. Maternal-Fetal Medicine (6
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationInterstitial Lung Disease in Infants and Children
Interstitial Lung Disease in Infants and Children David A. Mong, MD SUNDAY Andrew Mong MD Beyond the interstitium (path includes airways/airspace) Radiographic diffuse disease Adult Interstitial Lung Disease
More informationAn Update on Caffeine Therapy
An Update on Caffeine Therapy Emory University School of Medicine Atlanta, GA Wally Carlo, MD University of Alabama at Birmingham Department of Pediatrics Division of Neonatology wcarlo@peds.uab.edu Objectives
More informationLandmark articles on ventilation
Landmark articles on ventilation Dr Shrikanth Srinivasan MD,DNB,FNB,EDIC Consultant, Critical Care Medicine Medanta, The Medicity ARDS AECC DEFINITION-1994 ALI Acute onset Bilateral chest infiltrates PCWP
More informationMEDICAL POLICY I. POLICY POLICY TITLE POLICY NUMBER INHALED NITRIC OXIDE MP-4.021
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Inhaled nitric oxide may be considered medically necessary as
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adenovirus infections, inflammation due to, 701 702 Airway collapse of, hypoxic episodes in, 831 833 immaturity of, hypoxic episodes and, 831
More informationWheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis. Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine
Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine Asthma Defined National Asthma Education and Prevention
More informationUses 1,2,3 : Labeled: Prevention of respiratory distress syndrome in premature infants
Brand Name: Surfaxin Generic Name: lucinactant Manufacturer 1 : Discovery Laboratories, Inc. Drug Class 2,3 : Synthetic lung surfactant Uses 1,2,3 : Labeled: Prevention of respiratory distress syndrome
More informationA2b. PDA Management--A Reflection on the Evidence: Does it Help with Management? Session Summary. Session Objectives. References.
FANNP 23RD NATIONAL NNP SYMPOSIUM: CLINICAL UTE AND REVIEW A2b Management--A Reflection on the Evidence: Does it Help with Management? Alfonso Vargas, MD Neonatologist Pediatrix Medical Group, Tampa, FL
More informationSWISS SOCIETY OF NEONATOLOGY. Preterm infant with. pulmonary hypertension and hypopituitarism
SWISS SOCIETY OF NEONATOLOGY Preterm infant with pulmonary hypertension and hypopituitarism November 2007 2 Pilgrim S, Stocker M, Neonatal and Pediatric Intensiv Care Unit, Children s Hospital of Lucerne,
More informationIncidence of Bronchopulmonary Dysplasia in Korea
ORIGINAL ARTICLE Pediatrics http://dx.doi.org/1.3346/jkms.12.27.8.914 J Korean Med Sci 12; 27: 914-921 Incidence of Bronchopulmonary Dysplasia in Korea Chang Won Choi 1,2, Beyong Il Kim 1,2, Ee-Kyung Kim
More informationPAEDIATRIC RESPIRATORY FAILURE. Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre
PAEDIATRIC RESPIRATORY FAILURE Tang Swee Fong Department of Paediatrics University Kebangsaan Malaysia Medical Centre Outline of lecture Bronchiolitis Bronchopulmonary dysplasia Asthma ARDS Bronchiolitis
More informationClinical Use of Exogenous Surfactant (For Adults Only.) Is there a future?
Clinical Use of Exogenous Surfactant (For Adults Only.) Is there a future? Jim Lewis MD, FRCP Professor of Medicine and Physiology CRC Calgary, April 26, 2014 Financial Interest Disclosure (over the past
More informationNitric Resource Manual
Nitric Resource Manual OBJECTIVES Describe the biologic basis for inhaled nitric oxide therapy Describe the indications for inhaled nitric oxide therapy Describe the potential hazards, side effects and
More informationAdmission/Discharge Form for Infants Born in Please DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
Selection Criteria Admission/Discharge Form for Infants Born in 2016 To be eligible, you MUST answer YES to at least one of the possible criteria (A-C) A. 401 1500 grams o Yes B. GA range 22 0/7 31 6/7
More informationLung Wit and Wisdom. Understanding Oxygenation and Ventilation in the Neonate. Jennifer Habert, BHS-RT, RRT-NPS, C-NPT Willow Creek Women s Hospital
Lung Wit and Wisdom Understanding Oxygenation and Ventilation in the Neonate Jennifer Habert, BHS-RT, RRT-NPS, C-NPT Willow Creek Women s Hospital Objectives To review acid base balance and ABG interpretation
More informationPEDIATRIC RESPIRATORY ILLNESS MADE SIMPLE
Copyright 2012 Joel Berezow, MD and The Pediatrics for Emergency Physicians Network All rights reserved. Duplication in whole or in part, or electronic transmission in any form, is prohibited THE PEDIATRICS
More informationUpdate on ChILD. R. Paul Guillerman, MD Associate Professor Department of Pediatric Radiology
Update on ChILD R. Paul Guillerman, MD Associate Professor Department of Pediatric Radiology Objectives Review recent advances in the imaging of childhood interstitial lung disease (ChILD) Diseases under-recognized,
More informationNeonatal Resuscitation in What is new? How did we get here? Steven Ringer MD PhD Harvard Medical School May 25, 2011
Neonatal Resuscitation in 2011- What is new? How did we get here? Steven Ringer MD PhD Harvard Medical School May 25, 2011 Conflicts I have no actual or potential conflict of interest in relation to this
More informationInfant Nutrition & Growth to Optimize Outcome Fauzia Shakeel, MD
Infant Nutrition & Growth to Optimize Outcome Fauzia Shakeel, MD Neonatologist All Children s Hospital / Johns Hopkins Medicine Affiliate Assistant Professor, University of South Florida September 2014
More informationCONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEFINITION
CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) DEFINITION Method of maintaining low pressure distension of lungs during inspiration and expiration when infant breathing spontaneously Benefits Improves oxygenation
More information5th World Congress on Pediatric Critical Care
5th World Congress on Pediatric Critical Care Geneva - June 26, 2007 Thomas M. Berger, MD Neonatal and Pediatric Intensive Care Unit Children's Hospital of Lucerne Switzerland History of neonatal ventilation
More informationRESPIRATORY PHARMACOLOGY
Yerevan State Medical University Department of Anaesthesiology and Intensive Care Yerevan, Armenia RESPIRATORY PHARMACOLOGY Dr. Armen VAROSYAN Associate Professor, DEAA, PhD Lecture Outline Drugs stimulating
More information3/13/2009. Bronchopulmonary Dysplasia (BPD) Congenital Diaphragmatic Hernia. Congenital Heart Disease. Connective Tissue Disease.
Pulmonary vascular alterations in chronic lung disease: The clinical problem Fetal circulation-gas exchange occurs in the placenta David N. Cornfield, M.D. Anne T. and Robert M. Bass Professor of Pulmonary
More informationMFMU - Background. MFMU - Background MFMU GOALS
MFMU - Background Highlights From The MFM Units Network Ronald Wapner, MD Modern OB management (especially high risk pregnancies) has adopted principles of care, employed pharmaceuticals, applied methodologies
More informationResearch Roundtable Summary
Research Roundtable Summary 10 TENTH in a Series of Seminars on MCHB-funded Research Projects Early Cortisol Deficiency and Bronchopulmonary Dysplasia October 18, 1995 Parklawn Building Potomac Conference
More informationBronchopulmonary dysplasia: incidence and risk factors
Original article Arch Argent Pediatr 2017;115(5):476-482 / 476 Bronchopulmonary dysplasia: incidence and risk factors Pablo H. Brener Dik, M.D. a, Yeimy M. Niño Gualdron, M.D. a, María F. Galletti, M.D.
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationNon Invasive Ventilation In Preterm Infants. Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid
Non Invasive Ventilation In Preterm Infants Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid Summary Noninvasive ventilation begings in the delivery room
More informationObjectives. Case Presentation. Respiratory Emergencies
Respiratory Emergencies Objectives Describe how to assess airway and breathing, including interpreting information from the PAT and ABCDEs. Differentiate between respiratory distress, respiratory failure,
More informationSAMPLE. V.12.1 Special Report: Very Low Birthweight Neonates. I. Introduction
I. Introduction V.12.1 Special Report: Very Low Birthweight Neonates The delivery of a very low birth weight infant continues to present many challenges to families and health care providers in spite of
More informationADMISSION/DISCHARGE FORM FOR INFANTS BORN IN 2019 DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
1 Any eligible inborn infant who dies in the delivery room or at any other location in your hospital within 12 hours after birth and prior to admission to the NICU is defined as a "Delivery Room Death."
More informationA Preemie is out of the NICU Now What!? Care of the Ex Preterm Neonate
A Preemie is out of the NICU Now What!? Care of the Ex Preterm Neonate Shawn Hollinger, MD FAAP FRCPC Assistant Professor Neonatology Department of Pediatrics Adjunct Professor Obstetrics and Gynecology
More informationNew Zealand Data Sheet. Poractant alfa (Phospholipid fraction of porcine lung) 80 mg/ml
CUROSURF New Zealand Data Sheet Poractant alfa (Phospholipid fraction of porcine lung) 80 mg/ml Presentation Sterile suspension in single-dose vials for intratracheal or intrabronchial administration.
More informationMedical Follow-up of the High-Risk NICU Graduate
Medical Follow-up of the High-Risk NICU Graduate Silvia Fajardo-Hiriart, M.D. Medical Director High-Risk Infant Follow-Up/Early Intervention Program University of Miami Miller School of Medicine Department
More informationManagement of Respiratory Disease in the Term Infant
Management of Respiratory Disease in the Term Infant David Tingay 1. Neonatal Research, Murdoch Children s Research Institute, Melbourne 2. Neonatology, Royal Children s Hospital 3. Dept of Paediatrics,
More informationOutcomes From Severe ARDS Managed Without ECMO. Roy Brower, MD Johns Hopkins University Critical Care Canada Forum Toronto November 1, 2016
Outcomes From Severe ARDS Managed Without ECMO Roy Brower, MD Johns Hopkins University Critical Care Canada Forum Toronto November 1, 2016 Severe ARDS Berlin Definition 2012 P:F ratio 100 mm Hg Prevalence:
More informationDisclosure COULD AUTOMATED CONTROL OF OXYGEN LEVELS IMPROVE SURVIVAL AND REDUCE NEC? Oxygen Dependency
COULD AUTOMATED CONTROL OF OXYGEN LEVELS IMPROVE SURVIVAL AND REDUCE NEC? Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson Memorial Medical Center Sydney 206 Disclosure The University
More information